Notice Pursuant to The National Cooperative Research and Production Act of 1993-Subcutaneous Drug Development & Delivery Consortium, Inc., 57479 [2023-18088]

Download as PDF Federal Register / Vol. 88, No. 162 / Wednesday, August 23, 2023 / Notices Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, CONNECT Centre, Dublin, IRELAND, has been added as a party to this venture. Also, Accedian Networks, Inc., StLaurent, CANADA; Arm, Ltd., Cambridge, UNITED KINGDOM; DriveNets, Ra’anana, ISRAEL; and Macrometa, San Mateo, CA, have withdrawn as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and OGA intends to file additional written notifications disclosing all changes in membership. On March 31, 2022, OGA filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to section 6(b) of the Act on May 12, 2022 (87 FR 29180). The last notification was filed with the Department on March 28, 2022. A notice was published in the Federal Register pursuant to section 6(b) of the Act on June 12, 2023 (88 FR 38099). Suzanne Morris, Deputy Director Civil Enforcement Operations, Antitrust Division. [FR Doc. 2023–18087 Filed 8–22–23; 8:45 am] BILLING CODE P DEPARTMENT OF JUSTICE Antitrust Division lotter on DSK11XQN23PROD with NOTICES1 Notice Pursuant to The National Cooperative Research and Production Act of 1993—Electrified Vehicle and Energy Storage Evaluation Notice is hereby given that, on June 15, 2023, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Electrified Vehicle and Energy Storage Evaluation (‘‘EVESE’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Honda Development and Manufacturing of America, Raymond, OH, has been added as a party to this venture. VerDate Sep<11>2014 17:27 Aug 22, 2023 Jkt 259001 No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and EVESE intends to file additional written notifications disclosing all changes in membership. On September 24, 2020, EVESE filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to section 6(b) of the Act on October 15, 2020 (85 FR 65423). The last notification was filed with the Department on April 13, 2023. A notice was published in the Federal Register pursuant to section 6(b) of the Act on June 13, 2023 (88 FR 38535). Suzanne Morris, Deputy Director Civil Enforcement Operations, Antitrust Division. [FR Doc. 2023–18077 Filed 8–22–23; 8:45 am] BILLING CODE P DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to The National Cooperative Research and Production Act of 1993—Subcutaneous Drug Development & Delivery Consortium, Inc. Notice is hereby given that, on June 23, 2023, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Subcutaneous Drug Development & Delivery Consortium, Inc. (‘‘Subcutaneous Drug Development & Delivery Consortium, Inc.’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Becton, Dickinson and Company, Franklin Lakes, NJ, has been added as a party to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and Subcutaneous Drug Development & Delivery Consortium, Inc. intends to file additional written notifications disclosing all changes in membership. On October 26, 2020, Subcutaneous Drug Development & Delivery Consortium, Inc. filed its original PO 00000 Frm 00074 Fmt 4703 Sfmt 4703 57479 notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to section 6(b) of the Act on December 3, 2020 (85 FR 78148). The last notification was filed with the Department on December 21, 2022. A notice was published in the Federal Register pursuant to section 6(b) of the Act on January 25, 2023 (88 FR 4850). Suzanne Morris, Deputy Director Civil Enforcement Operations, Antitrust Division. [FR Doc. 2023–18088 Filed 8–22–23; 8:45 am] BILLING CODE P DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—Undersea Technology Innovation Consortium Notice is hereby given that, on July 5, 2023, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Undersea Technology Innovation Consortium (‘‘UTIC’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Applied Research Associates, Inc., Albuquerque, NM; Baker Manufacturing, Inc., Tacoma, WA; Custom Materials, Inc., Chagrin Falls, OH; Fairbanks Morse LLC, Beloit, WI; Florida Atlantic University, Boca Raton, FL; MBDA, Inc., Huntsville, AL; and Huntington Ingalls, Inc., Pascagoula, MS, have been added as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and UTIC intends to file additional written notifications disclosing all changes in membership. On October 9, 2018, UTIC filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to section 6(b) of the Act on November 2, 2018 (83 FR 55203). The last notification was filed with the Department on April 6, 2023. A notice was published in the Federal E:\FR\FM\23AUN1.SGM 23AUN1

Agencies

[Federal Register Volume 88, Number 162 (Wednesday, August 23, 2023)]
[Notices]
[Page 57479]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-18088]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to The National Cooperative Research and 
Production Act of 1993--Subcutaneous Drug Development & Delivery 
Consortium, Inc.

    Notice is hereby given that, on June 23, 2023, pursuant to section 
6(a) of the National Cooperative Research and Production Act of 1993, 
15 U.S.C. 4301 et seq. (``the Act''), Subcutaneous Drug Development & 
Delivery Consortium, Inc. (``Subcutaneous Drug Development & Delivery 
Consortium, Inc.'') has filed written notifications simultaneously with 
the Attorney General and the Federal Trade Commission disclosing 
changes in its membership. The notifications were filed for the purpose 
of extending the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances. 
Specifically, Becton, Dickinson and Company, Franklin Lakes, NJ, has 
been added as a party to this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and Subcutaneous Drug Development & 
Delivery Consortium, Inc. intends to file additional written 
notifications disclosing all changes in membership.
    On October 26, 2020, Subcutaneous Drug Development & Delivery 
Consortium, Inc. filed its original notification pursuant to section 
6(a) of the Act. The Department of Justice published a notice in the 
Federal Register pursuant to section 6(b) of the Act on December 3, 
2020 (85 FR 78148).
    The last notification was filed with the Department on December 21, 
2022. A notice was published in the Federal Register pursuant to 
section 6(b) of the Act on January 25, 2023 (88 FR 4850).

Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2023-18088 Filed 8-22-23; 8:45 am]
BILLING CODE P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.